NCT05233917 is a NA clinical trial of Olive oil use in Hyperlipidaemia, sponsored by Zhejiang University.

Who is sponsoring NCT05233917?

NCT05233917 is sponsored by Zhejiang University.

What drugs are being tested in NCT05233917?

Interventions in NCT05233917: Olive oil use, MLCT oil use.

What condition does NCT05233917 study?

NCT05233917 studies Hyperlipidaemia, Metabolic Syndrome.

Is NCT05233917 still recruiting?

NCT05233917 is currently completed. Last updated 15 November 2024.

Last reviewed 2024-11-15 · How we verify

NCT05233917

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Effects of Olive Oil and MLCT on Glycolipid Homeostasis in Patients With Metabolic Syndrome

Completed NA Last updated 15 November 2024

What this trial tests

NA trial testing Olive oil use in Hyperlipidaemia in 240 participants. Completed in 22 December 2023.

Timeline

9 June 2023

Primary endpoint
9 December 2023

22 December 2023

Quick facts

Lead sponsor	Zhejiang University
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	240
Start date	9 June 2023
Primary completion	9 December 2023
Estimated completion	22 December 2023
Sites	1 location across China

Drugs / interventions tested

Olive oil use
MLCT oil use

Conditions studied

Hyperlipidaemia — all drugs for Hyperlipidaemia →
Metabolic Syndrome — all drugs for Metabolic Syndrome →

Sponsor

Zhejiang University

Who can join

Adults 40 to 70, any sex, with Hyperlipidaemia or Metabolic Syndrome. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The type of cooking oil used is a crucial factor influencing dietary quality. The purpose of this study is to investigate the effects of olive oil and MLCT oil intervention on glucose and lipid homeostasis in patients with MetS.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Hyperlipidaemia

Currently open trials in the same condition.

NCT07339852 — Implementation and Evaluation of a Pharmacist-led Diabetes Care Pathway in Alberta Community Pharmacies · NA · recruiting

Other Zhejiang University trials

Trials by the same sponsor.

NCT07487402 — Safety and Efficacy of Metabolically Armed GPC3 CAR-T Cells Injection (Meta10-GPC3) in Patients With Unresectable Recurr · EARLY_PHASE1 · not yet recruiting
NCT07480044 — A Phase II Clinical Two-Stage Study of Transcranial Magnetic Stimulation in Preventing Postoperative Delirium in Elderly · NA · not yet recruiting
NCT07467005 — Video Double-Lumen Tube for Secondary Pulmonary Resection · NA · not yet recruiting
NCT07429461 — Clinical Study of SYNCAR-100 in the Treatment of Relapsed/Refractory Acute B-Lymphoblastic Leukemia · EARLY_PHASE1 · recruiting
NCT07240766 — HRS-4642 in Combination With Nimotuzumab and Chemotherapy for BRPC With KRAS G12D Mutation · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05233917 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Zhejiang University
Last refreshed: 15 November 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05233917.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing